A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion

Veronika Jenei1,2, Victoria Sherwood1,3, Jillian Howlin, Rickard Linnskog, Annette Såfholm, Lena Axelsson, and Tommy Andersson

Cell and Experimental Pathology, Department of Laboratory Medicine, Lund University, Clinical Research Centre, Malmö University Hospital, SE-20502 Malmö, Sweden

Edited by George Klein, Karolinska Institutet, Stockholm, Sweden, and approved September 29, 2009 (received for review August 19, 2009)

The influential role of Wnt5a in tumor progression underscores the requirement for developing molecules that can target Wnt5a-mediated cellular responses. In the aggressive skin cancer, melanoma, elevated Wnt5a expression promotes cell motility and drives metastasis. Two approaches can be used to counteract these effects: inhibition of Wnt5a expression or direct blockade of Wnt5a signaling. We have investigated both options in the melanoma cell lines, A2058 and HTB63. Both express Frizzled-5, which has been implicated as the receptor for Wnt5a in melanoma cells. However, only the HTB63 cell line expresses and secretes Wnt5a. In these cells, the cytokine, TGFβ1, controlled the expression of Wnt5a, but due to the unpredictable effects of TGFβ1 signaling on melanoma cell motility, targeting Wnt5a signaling via TGFβ1 was an unsuitable strategy to pursue. We therefore attempted to target Wnt5a signaling directly. Exogenous Wnt5a stimulation of A2058 cells increased adhesion, migration and invasion, all crucial components of tumor metastasis, and the Wnt5a-derived N-butyloxycarbonyl hexapeptide (Met-Asp-Gly-Cys-Glu-Leu; 0.766 kDa) termed Box5, signaling directly. Exogenous Wnt5a stimulation of A2058 cells increased adhesion, migration, and invasion, all crucial components of tumor metastasis, and the Wnt5a-derived N-butyloxycarbonyl hexapeptide (Met-Asp-Gly-Cys-Glu-Leu; 0.766 kDa) termed Box5, abolished these responses. Box5 also inhibited the basal migration and invasion of Wnt5a-expressing HTB63 melanoma cells. Box5 antagonized the effects of Wnt5a on melanoma cell migration and invasion by directly inhibiting Wnt5a-induced protein kinase C and Ca²⁺ signaling, the latter of which we directly demonstrate to be essential for cell invasion. The Box5 peptide directly inhibits Wnt5a signaling, representing an approach to anti-metastatic therapy for otherwise rapidly progressive melanoma, and for other Wnt5a-stimulated invasive cancers.

Wnt ligands comprise a family of 19 human secreted signaling proteins, which coordinate essential processes required for development and maintenance of tissue homeostasis. Misregulation of Wnt signaling can lead to cancer progression (1). The Wnt ligands are secreted glycoproteins that can be divided based on their ability to activate different intracellular signals, in a tissue-dependent manner. One group primarily activates canonical signaling that controls β-catenin stability, while the other is loosely described as β-catenin transcriationally independent (non-canonical Wnt signaling). However, cross-talk between the two signaling networks does exist (2).

Wnt5a is in most situations characterized as a non-canonical Wnt ligand that elicits intracellular signals through association with distinct receptors and co-receptors in a cell specific manner. Wnt5a has been shown to stimulate increases in intracellular Ca²⁺ levels in developmental models (3) and mammalian cell lines, including breast and thyroid cancer cells (4–6), giving rise to the model of a non-canonical Wnt/Ca²⁺ signaling pathway. Wnt5a-mediated intracellular increases in Ca²⁺ levels enables the activation of Ca²⁺-regulated proteins, such as protein kinase C (PKC) in a context dependent manner, as reviewed recently (7).

Wnt5a expression has been linked to cancer progression in a variety of tumor types, but its role in tumorigenesis is complex. In breast, colon, thyroid, and liver cancers, Wnt5a functions as a tumor suppressor (6, 8–10). However, in other cancers such as malignant melanoma, Wnt5a actually promotes cancer progression (11–13). Therefore depending on the type of cancer, Wnt5a signaling has the potential to be manipulated to block tumor progression, either by mimicking its effects as for example in breast cancer (4, 14) or, as in the case of melanoma, by inhibiting its function. Currently the molecular components of the Wnt5a signaling pathway in melanoma are not fully elucidated. It has been shown to signal through the G protein-coupled receptor, Frizzled-5 (FZD5), which results largely in a β-catenin-independent signaling response in melanoma cells (12). Moreover, Wnt5a stimulates PKC activation to induce an epithelial to mesenchymal transition, resulting in increased adhesion, migration, and invasion (12, 15). Furthermore, Wnt5a has been shown to control cell polarity, orientation, and directional movement in melanoma cells (16). These findings highlight how Wnt5a can increase melanoma metastasis, but it is still unknown how the ligand directly elicits these activities and how the expression of Wnt5a itself is controlled in these cells.

Although cutaneous melanoma represents only 4% of all diagnosed skin cancers, due to its highly metastatic nature it accounts for 80% of all skin cancer-related deaths (17). If the melanoma has metastasized to lymph nodes or distant organs there are very limited therapeutic options to prolong survival or cure the disease (18). Consequently, cutaneous malignant melanoma poses a serious healthcare issue, and it is imperative that new drug therapies are identified and developed that can antagonize the metastatic process. Currently, there is a lack of effective therapeutics for hindering the progression of metastatic melanoma.

Given the distinct lack of therapeutics available for melanoma progression and the potency of Wnt5a to increase melanoma cell invasiveness and metastasis, we believe that inhibition of Wnt5a expression and signaling would be an excellent therapeutic approach for this disease, a concept already suggested by others (19). The promise of such a therapeutic approach is highlighted by the striking ability of Wnt5a to increase melanoma metastases in vivo (19). To identify a compound capable of antagonizing the


Conflict of interest statement: V.J., V.S., J.H., A.S., and L.A. have filed a patent on Box5 and its use as an anti-metastatic compound.

This article is a PNAS Direct Submission.

This article contains supporting information online at www.pnas.org/cgi/content/full/0909409106DCSupplemental.

1V.J. and V.S. contributed equally to this work.

2Present address: Cancer Sciences Division, Southampton University School of Medicine, Somers Building, Southampton General Hospital, Tremona Road, SO16 6DY Southamp- ton, United Kingdom.

3To whom correspondence should be addressed. E-mail: victoria.sherwood@med.lu.se.
effects of Wnt5a in melanoma cells, we investigated the Wnt5a signaling pathway in more detail. Although we report here that signaling via the potent cytokine, tumor growth factor β1 (TGFβ1), controls Wnt5a expression, loss of TGFβ1 signaling led to unpredictable effects on melanoma cell motility, highlighting the importance of targeting Wnt5a signaling directly. Therefore, we have developed and characterized a Wnt5a-specific antagonist peptide with the capacity to inhibit Wnt/Ca\textsuperscript{2+} signaling in melanoma cells. The inhibition of these Wnt5a-induced signals significantly reduced Wnt5a-mediated migration and invasion of melanoma cells, essential events in tumor metastasis. We believe this peptide represents a candidate for the development of an anti-metastatic therapy for Wnt5a-stimulated invasive cancers such as malignant melanoma.

Results
Due to the strong correlation between elevated Wnt5a levels and enhanced melanoma progression (11, 13), we investigated how Wnt5a expression is controlled in melanoma cell lines to test if blocking its expression could be a means to control melanoma cell invasiveness. To begin, we identified two human melanoma cell lines with differential Wnt5a expression patterns: A2058 cells with low endogenous expression and HTB63 cells that express and secrete high levels of Wnt5a (Fig. S1). Both cell lines expressed the putative melanoma Wnt5a receptor, Frizzled5 (FZD5) (Fig. S1). MCF-7 breast cancer cells were used as a positive control (20) (Fig. S1). Aside from the Wnt5a expression, these cell lines are actually similar in other aspects. Both these lines were originally isolated from metastases of patients with cutaneous melanoma (21, 22), and both carry the V599E BRAF mutation (23). Interestingly, the anti-proliferative cyclin-dependent kinase inhibitor, p16\textsuperscript{ink4a}, is not expressed in the mouse mammary gland (25), and maintain Wnt5a expression during mammary tumor formation (26). We found that the selective TGFβ1 type I receptor inhibitor SB431542 and recombinant TGFβ1 decreased and induced Wnt5a expression in the HTB63 and A2058 cell lines, respectively (Fig. S2). These data demonstrate that TGFβ1 is a positive regulator of Wnt5a expression in human melanoma cells. In accordance, we demonstrated that TGFβ1 signaling could increase melanoma cell adhesion and migration (Fig. S3). Paradoxically, however, TGFβ1 signaling had a negative effect on melanoma cell invasion in a 3-D cell culture assay (Fig. S4), which has also been observed in murine melanoma cells (27). These findings suggest that TGFβ1 is an unpredictable target for blocking Wnt5a-mediated melanoma cell motility presumably due to its well characterized multiple downstream effects.

The above results made us conclude that direct targeting of Wnt5a signaling could provide a more direct and therefore potentially safer alternative for therapeutics that antagonize Wnt5a activity in melanoma cells. We set about developing a molecule with the capacity to antagonize Wnt5a-induced melanoma cell migration. We first ascertained that Wnt5a could increase adhesion and migration in A2058 melanoma cells (Fig. 1 A and B) as previously demonstrated in other melanoma cell lines (12). Previously we identified and characterized a Wnt5a-derived, N-formylated hexapeptide (Foxy5) (Fig. 1C) that functions as an agonist of Wnt5a signaling. This peptide mimics the anti-migratory and anti-invasive effects of Wnt5a in breast cancer cell lines (4, 14), and has anti-tumorigenic effects on...
breast cancer in vivo (14, 28). We found that Foxy5 could also mimic the pro-migratory effects of Wnt5a in A2058 melanoma cells (compare Fig. 1 B and D), suggesting this peptide functions as a Wnt5a agonist in diverse cell types. Interestingly, it has previously been shown that a formylated bacterial chemotactic peptide (formyl-Met-Leu-Phe), converted the molecule from an agonist to an antagonist analogue (29). Specifically, the modification involved substitution of the N-terminal formyl group for a t-butoxycarbonyl (t-boc) group. We hypothesized that such a change of Foxy5 could also change its Wnt5a agonist functions to that of an antagonist. We synthesized and purified such a t-boc-Met-Asp-Gly-Cys-Glu-Leu peptide, hereafter referred to as Box5 (Fig. 2A).

Dose-response analysis of Box5 indicated there was a strong inhibitory effect on Wnt5a-induced A2058 cell migration, with a statistically significant effective concentration at 100 μM (Fig. 2B). A t-boc-conjugated random hexamer (Met-Ser-Ala-Asp-Val-Gly; Boc-Ran) was unable to inhibit cell migration (Fig. 2B), confirming selectivity of Box5. Over a 48 h time course, Box5 had the ability to inhibit Wnt5a-mediated migration of A2058 cells (Fig. 2C) and could also antagonize the migration of HTB63 cells (endogenously secreting Wnt5a), to the same extent as changing the conditioned media (containing secreted Wnt-5a) to fresh serum-free media (lacking Wnt-5a) (Fig. 2D). However, Box5 did not affect the intrinsic migration of A2058 cells that lack endogenous Wnt5a expression (Fig. S5A). We also found that TGFβ1-mediated migration of A2058 cells could be blocked by preincubation with Box5 (Fig. S5B), further highlighting that direct blockade of Wnt5a-signaling downstream of TGFβ1 is an effective approach to inhibit Wnt5a-mediated melanoma migration.

During the metastatic process, tumor cells need to invade through the extracellular matrix, so we tested the efficacy of Box5 to block cell invasion in a 3-D matrigel cell culture model. Addition of Box5 abolished Wnt5a-induced invasion of A2058 cells, an effect not seen when the cells were stimulated with the canonical Wnt ligand, Wnt3a (Fig. 3A). Furthermore, Box5 also had the ability to inhibit invasion of HTB63 cells, by antagonizing the effects of endogenous and secreted Wnt5a from these cells (Fig. 3B). Collectively these data show that Box5 is a potent, selective antagonist of Wnt5a-mediated migration and invasion of melanoma cells, both of which are essential components of the metastatic process.

To identify the molecular basis for the antagonistic functions of Box5, we investigated components of Wnt5a signaling in melanoma cells that are essential for cell invasion. A recent study showed that Wnt5a signaling in melanoma cells resulted in cleavage of filamin A and remodeling of the cytoskeleton, leading to increased cell motility, where filamin A cleavage was mediated by Ca2+-activated proteases (30). This suggested that intracellular Ca2+ fluxes are required for Wnt5a-mediated cell invasion. We found that Wnt5a stimulated a rapid cytosolic Ca2+ signal in A2058 cells (Fig. 4A), which could be inhibited by preloading these cells with the intracellular Ca2+ chelator, MAPT (Fig. 4B). We used MAPT-Ca2+ chelation to assess the invasive capacity of melanoma cells in the absence of Wnt5a-induced Ca2+ signaling. The pro-invasive effect of Wnt5a on the A2058 cells was completely abolished by incubation with MAPT (Fig. 4C). This demonstrates that the Ca2+ signaling component of Wnt5a stimulation is required for mediating melanoma cell invasion.

Next we analyzed the ability of Box5 to modulate Wnt5a-induced Ca2+ signaling in melanoma cells. Box5 selectively inhibited Wnt5a-induced intracellular Ca2+ signaling, but not that induced by either endothelin-1 (ET-1) or carbachol (Fig. 5A), both of which trigger G protein coupled receptor-induced increases in cytosolic Ca2+ (Fig. 5B). Accumulated results revealed that there was >70% inhibition of Wnt5a-induced Ca2+
signaling by Box5, but the peptide had no such effect on the Ca\(^{2+}\) signal induced by either ET-1 or carbachol (Fig. 5B).

Previous studies have suggested that there is a downstream effect of Wnt-5a-induced PKC activation on the regulation of melanoma cell migration (12, 15). In the present study, we assessed Ser-152/156 phosphorylations of the endogenous PKC substrate, Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) (31), as a direct means of estimating the level of PKC activity. Wnt5a stimulation of A2058 cells resulted in increased phosphorylation of MARCKS, which was inhibited in the presence of the Box5 peptide (Fig. 5C). These data show that Box5 functions to inhibit melanoma cell invasion by directly antagonizing Wnt5a-stimulated Ca\(^{2+}\) and PKC signaling, both of which are essential for Wnt5a-mediated melanoma cell invasion. We conclude that Box5 functions as a selective antagonist of Wnt5a-induced melanoma cell migration and invasion by inhibiting Wnt5a signaling.

**Discussion**

Malignant melanoma is a particularly aggressive cancer, and once metastasis has occurred, there is an extremely poor overall prognosis with limited treatment options, highlighting the crucial need for new therapies to counteract the metastatic process in these patients. The fact that Wnt5a expression and signaling has been strongly associated with driving malignant melanoma metastasis (11–13, 15, 19), not only highlights the relevance of Wnt5a signaling in melanoma due to the multiple and unpredictable effects of this cytokine. We propose instead that direct blocking of Wnt5a signaling is a more effective approach for the development of anti-metastatic drugs in tumors that express high constitutive levels of Wnt5a.

Our study demonstrates that the Box5 hexapeptide effectively inhibits Wnt5a signaling in a selective and dose-dependent manner in melanoma cells, and is a direct antagonist of Wnt5a signaling. The cell lines we chose to test Box5 on were originally derived from cutaneous melanoma metastases with BRAF mutations, thus they represent the most common form of the malignancy and therefore our data suggests that Box5 could have broad potential as an anti-metastatic drug for melanoma. To test this, in vivo studies are required to help predict the potential clinical efficacy of the Box5 peptide. As such, we have currently initiated experiments using melanoma xenograft models to test the peptide in an in vivo setting. A previous study on substituting the N-terminal formyl group for different carbamate groups on
It is reasonable to also suggest that the present substitution of the carbonyl group. Wnt5a-derived agonist hexapeptide (4) modifies this peptide for antagonist activity based on the size and shape of the butyloxy-carbonyl group.

The Box5 peptide significantly inhibited Wnt5a-induced Ca2+ and PKC signaling, both of which are necessary for Wnt5a-mediated melanoma cell invasion. Intracellular Ca2+ and PKC signaling are often intimately linked events (7). Consequently, our present finding that the Wnt5a-induced Ca2+ signal is essential for Wnt5a mediated melanoma cell migration and invasion has several possible interpretations. Firstly, Wnt5a-induced Ca2+ signaling is required for subsequent activation of a Ca2+-sensitive PKC isofom(s). In accordance, Wnt5a has been shown to activate Ca2+ dependent PKC isoforms in melanoma cells (12). Alternatively, the essential role of the Wnt5a-induced Ca2+ signal is independent of PKC activation and instead required for Wnt-5a-induced remodeling of the cytoskeleton in a PKC-independent manner, which is essential for melanoma cell motility (30). Finally, of course both of these alternatives could be involved.

Although the FZD5 receptor has been implicated in Wnt5a signaling in melanoma cells (12), the precise receptors/co-receptors that are involved remain undetermined. Therefore our approach of developing a Wnt5a inhibitor was based on our previous identification of possible secondary/solvent accessible surface exposed regions in the Wnt5a molecule, as previously described (4). We believe that this ligand-focused approach, rather than one based on targeting a particular receptor, is a more relevant strategy based on current understanding. Box5 is derived from the Wnt5a agonist peptide, Foxy5, also developed in our lab (4). The two peptides share the same amino acid sequence but differ in that Foxy5 has a formyl group and Box5 a butyloxy-carbonyl group to the N-terminal methionine of this hexapeptide. Previously, we found that the effects of Foxy5 were lost if the cells were pretreated with a FZD5-specific blocking antibody, suggesting that Foxy5 mediates its effect on breast cancer cells via the G protein-coupled receptor FZD5 (4). The previous and present findings that the amino acid sequence is essential for the described effects of Foxy5 (4) and Box5, makes it logical to speculate that Box5 functions, like Foxy5, via binding to the FZD5 receptor. The relevance of this assumption is something we are actively investigating in our laboratory at present.

It should be noted that not all melanoma metastasis express high levels of Wnt5a (13, 19); this finding is of clinical relevance. With Box5 targeting, the need to screen patient’s tumors for Wnt5a expression and active signaling will be required to identify those patients most likely to benefit from Box5 chemotherapy. Whilst Box5 may not be a suitable target for all patients suffering from melanoma, the most vulnerable group are most likely to benefit from the treatment given that Wnt5a expression is strongly associated with poor outcome (13). In a clinical setting, Box5 would probably be used in conjunction with existing therapies, defining it as an adjuvant agent for melanoma therapy.

In summary, we describe a hexapeptide (Box5) that antagonizes signaling by the pro-invasive signaling ligand, Wnt5a, in melanoma cells. The effects of Box5 suggest it could be a lead compound for the development of anti-metastatic therapies for malignant melanoma patients. Most cancer-related deaths are due to metastatic spread, highlighting the need for effective anti-metastatic therapeutics. Wnt5a has also been implicated in promoting cell migration in other tumors such as prostate (32), pancreatic (33), gastric (34), and non-small-cell lung cancers (35), suggesting that Box5 could have far wider potential use as an anti-metastatic drug. In a broader context, Wnt5a is also thought to promote chronic inflammatory diseases such as psoriasis and rheumatoid arthritis (36–38), highlighting further possible applications for Box5.
Materials and Methods

Cells, Chemicals, and Peptides. Details of cells, culture conditions, and chemicals are provided in SI Materials and Methods. The Fox5, Box5, and Boc-Ran peptides were synthesized by Inbiolabs (several different production batches of the peptides were used). Peptides were purified by reverse-phase high performance liquid chromatography and the purity of each synthesis was >95% (mass spectrometry, Inbiolabs).

Cell Adhesion Assay. Pretreated cells, stimulated as described for each experiment were detached with versene, counted, resuspended in growth media at 30,000 cells/well, and plated in a 96-well plate. The cells were allowed to adhere for 1 h using normal growth conditions and then the non-adherent cells washed away with PBS. The remaining, adherent cells were then fixed in 1% glutaraldehyde for 10 min and stained with 0.5% crystal violet in 20% methanol. After washing with PBS, the stain from each well was dissolved in 50% acetic acid. The absorbance of the dissolved stain was measured in a plate reader (Fluoscan, BMG Lab Technologies) at 544 nm. Individual samples were analyzed in quadruplicate against a background of blank wells.

Wound Healing/Cell Migration. Confluent cell monolayers had a scratch inflicted and were incubated in serum-free media containing the relevant stimuli for each experiment. Images of the scratches were taken as indicated. Wound-healing data are expressed as a percentage of the wound and migration was measured as percentage of the scratch area closed over time. The wound-healing data are expressed as a percentage of the wound area closed after 0, 16, 24, 40, and 48 h.

Cell Invasion. Three-dimensional invasion assays were carried out using Matrigel invasion chambers (BD) with 8-µm pore size membranes, in a 24-well plate format. Cell invasion was performed as described previously (5). Briefly, cells were resuspended in serum-free media (25,000 cells/well). For treatments with Box5 and MAPT/AM, the cells were preincubated for 40 min with gentle agitation, and stimulated as required upon seeding. Cells were allowed to invade for 24 h, fixed (4% paraformaldehyde), stained with crystal violet, and counted. As an additional control for the migration and invasion assays, 0.2 µg/mL of recombinant Wnt5a (rWnt5a) was not found to affect cell proliferation or apoptosis.

Determination of Cytosolic Free Calcium Levels. This was carried out as previously described (5). Fura-2 fluorescence was measured during stimulations with Wnt5a, endothelin-1, or carbachol. Cells were stimulated with half the concentration of rWnt5a as used for most other assays, so that similar Ca2+ responses as with ET-1 (10 nM) and carbachol (5 µM) could be observed. For experiments with MAPT/AM, cells were incubated with 10 µM MAPT/AM in C2-containing medium for 30 min, after initial incubation with 4 µM Fura-2/AM. All Ca2+ traces shown are representative of a minimum of three repeats for each experimental condition tested.

Western Blotting. Cells were lysed in 50 mM Tris-HCl (pH 7.5), 1% Triton X-100, 100 mM NaCl, 10 mM MgCl2, 20% glycerol, 1 mM Na3VO4, and protease inhibitors (20 µg/mL aprotinin, 1 µg/mL leupeptin, 2.5 mM benzamidine, and 2 mM Pefabloc), and spun at 15,000 rpm for 5 min at 4 °C. For blotting of secreted proteins, cell medium was first concentrated in Amicon Ultra-15 (Millipore), according to the manufacturer’s instructions. Immunoblotting was conducted as previously described. The following symbols were used to denote statistical significance on the graphs: * P < 0.05; ** P < 0.01; *** P < 0.001.

Acknowledgments. We thank Kristi Kurg at Inbiolabs for excellent technical assistance. The work was supported by the Swedish Cancer Foundation (to T.A.), Swedish Research Council (to T.A.), Malmö University Hospital Research Foundations (to T.A.), Gunnar Nilsson’s Cancer Foundation (to T.A.), and the Royal Physiographic Society (to V.S., V.J.H., and J.H.).
Supporting Information

Jenei et al. 10.1073/pnas.0909409106

SI Materials and Methods

Cells, Antibodies, and Chemicals. The malignant melanoma cell line, HTB63, and the breast cancer cell line, MCF7, were obtained from the American Type Tissue Culture Collection (ATCC), and were grown according to ATCC recommendations. The A2058 malignant melanoma cell line was a generous gift of Laszló Kopper from the Department of Pathology and Experimental Cancer Research, Semmelweis University, Hungary, and grown in RPMI medium 1640. All growth medium contained 5U/mL penicillin, 0.5 U/mL streptomycin, 10% fetal bovine serum, and 2 mM glutamine. All cell culture reagents were obtained from Sigma-Aldrich, and cells incubated at 37 °C in a humidified atmosphere of 5% CO2. Serum-free conditioned medium from the HTB63 cells was prepared from 70% confluent cells growing for 48 h. The primary antibodies, anti-β-actin, clone AC-15 (Sigma-Aldrich), and anti-phospho-MARCKS (P-MARCKS; Cell Signaling Technology) were used at 1 in 25,000 and 1 in 1,000 for Western analysis, respectively. The Wnt5a antibody was developed by our laboratory against amino acids 275–290, as described previously (1), and used at a dilution of 1 in 1,000 for Western blotting. All peroxide-conjugated IgG secondary antibodies were obtained from Dako Chemicals and used at a concentration of 1 in 10,000 for Western analysis. Unless otherwise stated, stimulation of cells with recombinant Wnt5a (rWnt5a; R&D Systems) was carried out at a concentration of 0.2 μg/mL. Recombinant Wnt3a (rWnt3a) and TGFβ1 (also R&D Systems) were used at concentrations of 0.05 μg/mL and 5 ng/mL, respectively unless otherwise stated. The TGFβ1-type1 receptor inhibitor, SB431542 (Tocris Cookson), was used at a concentration of 10 μM. ET-1, carbachol, Fura-2/AM, and MAPT/AM were all purchased from Sigma-Aldrich, as too were all other analytical grade chemicals (if not otherwise stated).

Reverse Transcriptase PCR (RT-PCR). RNA extraction, RT reaction and PCR methods were carried out as described previously (2). The specific PCR primers were as follows: Wnt-5a forward: 5'-GGATTGTAAACTCAACTCTC-3'; Wnt-5a reverse: 5'-ACACCTTCTCCAACAGGCC-3'; β-actin forward: 5'-TTCAACCACCCAGCCATGTA-3'; β-actin reverse: 5'-TTGCCAATGGTGATGACCTG-3'; FZD-2 forward: 5'-ACATCGCCTACAACGACC-3'; FZD-2 reverse: 5'-CTCGGCCGAAACTTGTAGC-3'; Frizzled-5 forward: 5'-ACACCCCTCTCAACAACCAG-3'; Frizzled-5 reverse: 5'-CGTAGTGATGTGTTGTC-3'. For FZD2 and FZD5, the reactions were performed on 3.5 times the amount of cDNA used for the β-actin control.

Characterization of the A2058 and HTB63 cell lines. (A) A2058 and HTB63 melanoma cells have low, and have expression of Wnt5a mRNA, respectively as analyzed by RT-PCR. MCF-7 breast cancer cells were used as a positive control for the Wnt5a transcript. All cell lines express FZD5 and FZD2 at the mRNA level. Reactions performed with (+ RT) and without (-RT) reverse transcriptase. (B) Corresponding Wnt5a protein levels, using recombinant Wnt5a (rWnt5a) as a positive control, as shown by Western analysis. (C) Western analysis of serum-free culture media collected from A2058 and HTB63 cells showing the absence and presence of secreted Wnt5a from these cell lines, respectively.
Fig. S2.  TGFβ1 up-regulates Wnt5a in human melanoma cell lines. (A) Western analysis of Wnt5a showing the effects of 24-h stimulation of A2058 cells (lacking endogenous expression of Wnt5a) with increasing concentrations of TGFβ1. (B) Western analysis of Wnt5a showing the effects of 4- and 5-day treatments of the selective TGFβ1 antagonist, SB431542 (10 μM), on HTB63 cells (these cells have endogenous expression of Wnt5a).
Fig. S3. TGFβ1 promotes melanoma cell adhesion and migration. (A) Adhesion assay of A2058 cells stimulated with the indicated concentrations of TGFβ1. (B) Wound-healing assay of A2058 cells stimulated with (open squares) and without (filled circles) TGFβ1 at a concentration of 5 ng/mL. (C) Wound-healing assay of HTB63 cells in the absence (filled circles) or presence (open squares) of 10 μM SB431542.
Fig. S4. TGFβ1 inhibits melanoma cell invasion. Melanoma cell invasion was assessed using BD Matrigel invasion chambers. A2058 cells were incubated with or without 5 ng/mL of TGFβ1, and HTB63 cells with or without 10 μM SB431542, during the 24 h invasion assay.
Fig. S5. Box5 has no effect on the basal migration of A2058 melanoma cells, but can inhibit TGFβ1-induced migration. (A) Wound-healing analysis of A2058 cells stimulated with (open squares) or without (filled circles) 100 μM Box5. (B) Wound-healing assay of A2058 cells preincubated with or without 100 μM Box5 for 40 min, and then further stimulated with or without 5 ng/mL TGFβ1, as indicated. All wound-healing data are expressed as percentage of the wound area closed after 0, 16, 24, 40, and 48 h.
Fig. S6. Endothelin-1 and carbachol increase cytosolic Ca\(^{2+}\) in A2058 melanoma cells. (A) Representative Ca\(^{2+}\) trace from A2058 cells stimulated with 10 nM ET-1 (addition as indicated by arrow), using a Photon Technology International (PTI) imaging system. (B) Representative Ca\(^{2+}\) trace from A2058 cells stimulated with 5 \(\mu\)M carbachol (addition as indicated by arrow), also analyzed using a PTI.